Teleflex completes enrollment in BIOMAG-LL trial of longer Freesolve scaffold
TFX•Teleflex completed enrollment in the BIOMAG-LL study of its Freesolve resorbable magnesium scaffold for longer coronary lesions. No results have been presented; follow-ups are planned through 60 months, with an initial 12-month clinical endpoint.
1. Trial enrollment completed
The BIOMAG-LL study is designed to assess the safety and clinical performance of longer Freesolve scaffold sizes intended to reduce reliance on permanent stents. The longer-length devices are also being evaluated in the ongoing BIOMAG-III pivotal trial, which is enrolling in the US and other markets. Freesolve is currently marketed only in CE-mark accepting countries.
